Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1296739 | 0.91 | GPR119 (0.49) | GPR119KCNH2CHRM2CHRM1CHRM3 | |
| SCHEMBL1296033 | 0.90 | GPR119 (0.43) | GPR119KCNH2NNMTFFAR4 | |
| SCHEMBL1295102 | 0.89 | GPR119 (0.47) | GPR119KCNH2CHRM2CHRM1CHRM3 | |
| SCHEMBL1295947 | 0.85 | GPR119 (0.48) | GPR119KCNH2CHRM2CHRM1CHRM3 | |
| SCHEMBL1295722 | 0.84 | GPR119 (0.44) | GPR119KCNH2CHRM2CHRM1CHRM3 | |
| SCHEMBL1295657 | 0.83 | GPR119 (0.58) | GPR119KCNH2CHRM2CHRM1CHRM3 | |
| SCHEMBL1713024 | 0.81 | NNMT (0.38) | GPR119KCNH2NNMTFFAR4 | |
| SCHEMBL1296300 | 0.81 | GPR119 (0.43) | GPR119KCNH2FFAR4PPARGPPARD | |
| SCHEMBL12104047 | 0.80 | NNMT (0.39) | GPR119NNMTPPARGPPARDPPARA | |
| SCHEMBL1295967 | 0.80 | GPR119 (0.39) | GPR119FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| WO-2010004343-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | GPR119, GPR27, GLP1R | GPR119 1/4885KCNH2 1416/4885NNMT 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.